March 11 (Reuters) – Stemcentrx Inc, a San Fransisco-based biotechnology startup, is pursuing strategic alternatives including a sale, the Wall Street Journal reported.
The post Startup Stemcentrx exploring strategic options, including sale-WSJ appeared first on NASDAQ.